Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma, and progression-free survival was prolonged but did not reach the prespecified improvement target.
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
In a cohort of patients with grade 2 glioma who were younger than 40 years of age and had undergone subtotal tumor resection or who were 40 yearsof age or older, progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy than amongThose who received radiation therapy alone.
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
The data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas is reviewed and ongoing studies that are testing resistance-modulating strategies are described.
Chemoradiotherapy in malignant glioma: standard of care and future directions.
- R. Stupp, M. Hegi, M. Gilbert, A. Chakravarti
- Biology, MedicineJournal of Clinical Oncology
- 10 September 2007
Although the relative contribution of the concomitant and the adjuvant chemotherapy, respectively, cannot be assessed, the early introduction of chemotherapy and the simultaneous administration with radiotherapy appear to be key for the improvement of outcome.
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
This study did not demonstrate improved efficacy for DD temozolomide for newly diagnosed GBM, regardless of methylation status, but it did confirm the prognostic significance of MGMT methylation.
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
EGFRvIII-targeted vaccination in patients with GBM warrants investigation in a phase III, randomized trial.
Association and Interactions between DNA Repair Gene Polymorphisms and Adult Glioma
- Yanhong Liu, M. Scheurer, M. Bondy
- BiologyCancer Epidemiology, Biomarkers and Prevention
- 1 January 2009
Results suggest that polymorphisms in DNA repair genes may act individually or together to contribute to glioma risk.